The trajectory of Sildenafil presents a complex picture for those considering investment. While the initial introduction generated significant gains, the expiration of its intellectual property protection opened the floodgates to generic versions, dramatically diminishing sales. This poses a unique risk for pharmaceutical companies depending on com

The story of Viagra, and its parent company copyright, presents a challenging case study for investors. At first a blockbuster drug, generating billions in sales , its patent expiration created a deluge of lower-priced alternatives , significantly eroding its position . While certain pharmaceutical companies may seek to capitalize on similar condit